Biorasi’s Oncology Center of Excellence remains at the forefront of this exciting field. Our team of clinicians, program managers and other experts stay up to date on the latest developments, from Tumor Infiltrating Lymphocyte (TIL) therapy to gene therapy advances. This experience, combined with Biorasi’s worldwide site network and data-driven approach, allows us to guide oncology programs to success—on time and on budget.
A clinical trial's operational efficiency depends on a solid oversight and response mechanism. Without vigilant monitoring, patient safety, data integrity, and the overall health of your trial come into jeopardy.
It's rare for any large project that involves hundreds of individuals and multiple locations to proceed without some sort of hiccup. Budgets get stretched, schedules run behind, key [...]
Movement disorders such as Parkinson’s disease, ataxias, tremor, dystonia, tics, Tourette’s, and dozens of rare diseases, affect nearly 40 million Americans. They're usually chronic, often progressive, and rarely [...]
Eczema affects more people in the United States than diabetes (10.1 vs. 9.4 million)1,2. More than 8 million Americans have psoriasis.3 Considering how common some skin conditions are, [...]
Have you ever put off talking to your significant other about expensive-but-necessary home repairs, for fear they'll hit the (leaking) roof? Most of us have, and if we [...]
Each year, doctors diagnose about 1,000 Americans with cystic fibrosis, a rare hereditary disease that affects about 30,000 people in the United States. Thanks to advances in treatment, [...]
The numbers vary but multiple surveys confirm what we all know: patient recruitment is one of the most challenging and important aspects of running a clinical trial. A [...]